Zhendong Pharmaceutical disclosed its 2026 half-year report, with first-half revenue of 1.097 billion yuan and a net loss attributable to the parent company of 92.7255 million yuan. The company said performance was under pressure mainly because core product prices and sales volumes faced temporary pressure, compounded by the proactive reduction of some long-term loss-making non-core low-efficiency businesses and a decline in financial asset returns. R&D investment reached 113 million yuan, up 23.43% year on year, and 21 projects are currently in clinical trials or registration application stages. Several new products completed market launches, including full market launches of compound pancreatin powder and enzalutamide soft capsules, while colloidal bismuth pectin in dual dosage forms was newly included in the National Essential Medicines List, and compound sodium picosulfate granules obtained the agency rights for Ferring's original bowel preparation product Picolax.
Shanxi Zhendong PharmaceuticalFirst-half net loss of 92.7 million yuan due to price and volume pressure on core products, reduced non-core businesses, and lower financial asset returns.
